vs
Side-by-side financial comparison of BV Financial, Inc. (BVFL) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $10.5M, roughly 1.3× BV Financial, Inc.). BV Financial, Inc. runs the higher net margin — 45.6% vs -34.7%, a 80.3% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 9.2%). Over the past eight quarters, BV Financial, Inc.'s revenue compounded faster (11.1% CAGR vs -26.3%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
BVFL vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.5M | $13.8M |
| Net Profit | $4.8M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | 66.9% | -18.5% |
| Net Margin | 45.6% | -34.7% |
| Revenue YoY | 9.2% | 73.8% |
| Net Profit YoY | 146.2% | -141.1% |
| EPS (diluted) | $0.52 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.5M | $13.8M | ||
| Q3 25 | $10.0M | $12.5M | ||
| Q2 25 | $9.9M | $9.7M | ||
| Q1 25 | $9.2M | $8.8M | ||
| Q4 24 | $9.7M | $7.9M | ||
| Q3 24 | $10.0M | $7.0M | ||
| Q2 24 | $9.5M | $7.3M | ||
| Q1 24 | $8.5M | $25.4M |
| Q4 25 | $4.8M | $-4.8M | ||
| Q3 25 | $3.7M | $-638.0K | ||
| Q2 25 | $2.9M | $-3.2M | ||
| Q1 25 | $2.1M | $-1.2M | ||
| Q4 24 | $2.0M | $-2.0M | ||
| Q3 24 | $3.8M | $-5.7M | ||
| Q2 24 | $3.4M | $-5.6M | ||
| Q1 24 | $2.6M | $12.8M |
| Q4 25 | 66.9% | -18.5% | ||
| Q3 25 | 51.5% | -1.5% | ||
| Q2 25 | 39.9% | -28.3% | ||
| Q1 25 | 29.4% | -9.2% | ||
| Q4 24 | 29.5% | -11.8% | ||
| Q3 24 | 52.4% | -74.6% | ||
| Q2 24 | 49.6% | -69.4% | ||
| Q1 24 | 42.1% | 54.2% |
| Q4 25 | 45.6% | -34.7% | ||
| Q3 25 | 37.2% | -5.1% | ||
| Q2 25 | 29.0% | -32.7% | ||
| Q1 25 | 22.9% | -13.3% | ||
| Q4 24 | 20.2% | -25.0% | ||
| Q3 24 | 38.0% | -82.2% | ||
| Q2 24 | 35.8% | -76.5% | ||
| Q1 24 | 30.1% | 50.6% |
| Q4 25 | $0.52 | $-0.17 | ||
| Q3 25 | $0.41 | $-0.02 | ||
| Q2 25 | $0.29 | $-0.11 | ||
| Q1 25 | $0.21 | $-0.04 | ||
| Q4 24 | $0.18 | $-0.02 | ||
| Q3 24 | $0.35 | $-0.21 | ||
| Q2 24 | $0.32 | $-0.20 | ||
| Q1 24 | $0.24 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.7M | $36.8M |
| Total DebtLower is stronger | $35.0M | — |
| Stockholders' EquityBook value | $183.8M | $35.5M |
| Total Assets | $912.2M | $70.6M |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.7M | $36.8M | ||
| Q3 25 | $63.5M | $21.9M | ||
| Q2 25 | $56.3M | $18.7M | ||
| Q1 25 | $70.8M | $22.7M | ||
| Q4 24 | $70.5M | $26.6M | ||
| Q3 24 | $94.1M | $40.3M | ||
| Q2 24 | $90.6M | $43.1M | ||
| Q1 24 | $78.8M | $51.2M |
| Q4 25 | $35.0M | — | ||
| Q3 25 | $35.0M | $19.4M | ||
| Q2 25 | $35.0M | $19.4M | ||
| Q1 25 | $49.9M | $19.4M | ||
| Q4 24 | $49.9M | $19.3M | ||
| Q3 24 | $34.8M | $32.1M | ||
| Q2 24 | $34.8M | $31.8M | ||
| Q1 24 | $34.8M | $31.3M |
| Q4 25 | $183.8M | $35.5M | ||
| Q3 25 | $190.2M | $-4.5M | ||
| Q2 25 | $198.0M | $-7.5M | ||
| Q1 25 | $198.1M | $-5.9M | ||
| Q4 24 | $195.5M | $-5.9M | ||
| Q3 24 | $209.7M | $-5.2M | ||
| Q2 24 | $205.5M | $-1.4M | ||
| Q1 24 | $201.8M | $3.0M |
| Q4 25 | $912.2M | $70.6M | ||
| Q3 25 | $909.4M | $49.3M | ||
| Q2 25 | $908.3M | $44.9M | ||
| Q1 25 | $921.9M | $46.4M | ||
| Q4 24 | $911.8M | $44.9M | ||
| Q3 24 | $892.7M | $58.9M | ||
| Q2 24 | $897.2M | $63.2M | ||
| Q1 24 | $892.5M | $69.2M |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.17× | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.0M | $-6.0M |
| Free Cash FlowOCF − Capex | $18.8M | — |
| FCF MarginFCF / Revenue | 178.2% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 3.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.0M | $-6.0M | ||
| Q3 25 | $8.4M | $1.5M | ||
| Q2 25 | $2.7M | $-3.7M | ||
| Q1 25 | $4.4M | $-4.3M | ||
| Q4 24 | $16.1M | $-1.5M | ||
| Q3 24 | $6.1M | $-2.2M | ||
| Q2 24 | $1.5M | $-8.4M | ||
| Q1 24 | $4.6M | $39.0M |
| Q4 25 | $18.8M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $2.6M | — | ||
| Q1 25 | $4.2M | — | ||
| Q4 24 | $15.5M | — | ||
| Q3 24 | $6.0M | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $4.1M | — |
| Q4 25 | 178.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 46.0% | — | ||
| Q4 24 | 160.0% | — | ||
| Q3 24 | 59.6% | — | ||
| Q2 24 | 15.2% | — | ||
| Q1 24 | 48.4% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 3.96× | — | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | 8.23× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 1.77× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
